Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Lixisenatide for type 2 diabetes mellitus

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Will novel oral formulations change the management of inflammatory bowel disease?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mometasone furoate nasal spray for the treatment of asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is an increasing health problem worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiological traits of T2DM. Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM. AREAS COVERED: Pharmacological, preclinical and clinical evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed. Available data and pending clinical development are summarized, critically appraised and compared to competitor drugs. The most relevant papers and meeting abstracts published up to November 2010 are used as sources for this review. EXPERT OPINION: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin. However, limited data with the intended once-daily 20 μg subcutaneous dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments. It remains to be established whether the slightly differing chemical properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Investigational Drugs
Vol/bind20
Udgave nummer4
Sider (fra-til)549-57
Antal sider9
ISSN1354-3784
DOI
StatusUdgivet - 1 apr. 2011

ID: 32263543